Sign in

    David Bautz • Zacks Small-Cap Research

    David Bautz's questions to X4 Pharmaceuticals Inc (XFOR) leadership

    David Bautz's questions to X4 Pharmaceuticals Inc (XFOR) leadership • Q4 2024

    Question

    David Bautz of Zacks Small-Cap Research asked about 2025 sales goals for XOLREMDI, data on patient prescription refill rates, and whether the revised primary outcome for the 4WARD trial could affect the potential label for chronic neutropenia.

    Answer

    Mark Baldry (Executive) and Paula Ragan (Executive) explained that no formal sales guidance is being provided, as the focus is on building a new market through education. They noted patient adherence is high. Christophe Arbet-Engels (Executive) stated the trial's endpoint change is not expected to impact the potential label, as the full data package will be submitted.

    Ask Fintool Equity Research AI

    David Bautz's questions to X4 Pharmaceuticals Inc (XFOR) leadership • Q3 2024

    Question

    David Bautz of Zacks Investment Research asked if the company would provide 2025 sales guidance for XOLREMDI and whether any infection data was collected in the Phase II study, particularly for patients with reduced G-CSF.

    Answer

    CEO Paula Ragan stated that the company is not providing 2025 sales guidance at this time but will offer more commercial details heading into the new year. She explained that the Phase II study was not designed to assess infection rates, but highlighted that the observed robust increase in functional neutrophils is a proven correlate for infection risk reduction, giving them high confidence for the Phase III trial.

    Ask Fintool Equity Research AI

    David Bautz's questions to X4 Pharmaceuticals Inc (XFOR) leadership • Q2 2024

    Question

    David Bautz inquired about the mechanics of how XOLREMDI prescriptions are filled, such as on a monthly basis, and how the company recognizes revenue in relation to those prescription fills.

    Answer

    President and CEO Dr. Paula Ragan explained that it was too early to disclose the specific play-by-play of patient prescriptions. She noted that the current revenue figure reflects a blend of both inventory stocking at the specialty pharmacy and revenue from individual patients on therapy. Dr. Ragan indicated that more detailed metrics to help with forecasting may be provided later in the year or in 2025.

    Ask Fintool Equity Research AI